Malignant ascites: pathophysiology and treatment

Monoclonal Antibodies in Gynecological Cancer: A Critical Point of View

(2011) Filippo Bellati et al.   Clinical & Developmental Immunology

Cetuximab in the treatment of patients with colorectal cancer

(2011) Christopher R Garrett et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer

(2011) Haruhiko Imamoto et al.   Gastric Cancer

Recurrent Ovarian Cancer: When and How to Treat

(2011) Marcia Hall et al.   Current Oncology Reports

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy

(2010) Diane Seimetz et al.   CANCER TREATMENT REVIEWS

Pseudomyxoma peritonei: A French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy

(2010) D. Elias et al.   EJSO

Advanced cytoreduction as surgical standard of care and hyperthermic intraperitoneal chemotherapy as promising treatment in epithelial ovarian cancer

(2010) M. Deraco et al.   EJSO

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Management of ascites due to gastrointestinal malignancy

(2009) MuhammadW Saif et al.   ANNALS OF SAUDI MEDICINE

Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?

(2009) Terence C. Chua et al.   ANNALS OF SURGERY

Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: A pilot study

(2009) A. Fagotti et al.   GYNECOLOGIC ONCOLOGY

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: Multi-Institutional Experience

(2009) Tristan D. Yan et al.   JOURNAL OF CLINICAL ONCOLOGY

Indwelling Catheters for the Management of Refractory Malignant Ascites: A Systematic Literature Overview and Retrospective Chart Review

(2009) Nicole D. Fleming et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: A multi-institutional retrospective analysis in 52 patients

(2009) M. Valle et al.   JOURNAL OF SURGICAL ONCOLOGY

Intraperitoneal VEGF Inhibition Using Bevacizumab: A Potential Approach for the Symptomatic Treatment of Malignant Ascites?

(2009) S. Kobold et al.   ONCOLOGIST

Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of malignant ascites secondary to unresectable peritoneal carcinomatosis from advanced gastric cancer

(2007) E. Facchiano et al.   EJSO